Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v25.i3.20
pages 183-214

iNKT-Cell Responses to Glycolipids

Vrajesh V. Parekh
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232
Michael T. Wilson
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232
Luc Van Kaer
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232

Краткое описание

Invariant natural killer T (iNKT) cells are an unusual group of T lymphocytes that recognize glycolipid antigens presented by the major histocompatibility complex class I-related protein CD1d. Because iNKT cells play a regulatory role in the immune system, they are attractive targets for immunotherapy. The marine-sponge-derived glycolipid α-galactosylceramide (α-GalCer) potently activates iNKT cells. In vivo administration of α-GalCer to mice or humans results in rapid and robust cytokine secretion by iNKT cells, followed by the activation of a variety of cell types of the innate and adaptive immune systems. These potent immunomodulatory activities of α-GalCer are being exploited for therapeutic purposes. Preclinical studies in mice have demonstrated that α-GalCer and related glycolipids can protect mice against a variety of diseases, including cancer, infections, and several autoimmune and inflammatory conditions. Although α-GalCer treatment of mice is associated with unwanted side-effects, it has been proven safe in clinical trials with cancer patients. These studies have raised significant enthusiasm for the development of effective and safe iNKT-cell-based immunotherapies for a variety of human diseases.

Articles with similar content:

Regulation of Antigen-Specific Regulatory T-Cell Induction via Nasal and Oral Mucosa
Critical Reviews™ in Immunology, Vol.24, 2004, issue 3
Janneke N. Samsom
Application of Natural Killer T Cells in Antitumor Immunotherapy
Critical Reviews™ in Immunology, Vol.27, 2007, issue 6
Se-Ho Park, Changwan Hong
Nonmyeloablative Blood Stem Cell Transplantation as Adoptive Allogeneic Immunotherapy for Metastatic Renal Cell Carcinoma
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Richard W. Childs
The Role of Invariant NKT Cells in Allogeneic Hematopoietic Stem Cell Transplantation
Critical Reviews™ in Immunology, Vol.32, 2012, issue 2
Aristeidis Chaidos, Anastasios Karadimitris
Immunomodulation of Experimental Autoimmune Diseases via Oral Tolerance
Critical Reviews™ in Immunology, Vol.20, 2000, issue 1
Yehuda Shoenfeld, Ilan Krause, Miri Blank